The $865B Opportunity: Why Quality Data is the Foundation of Next-Gen Antibody Development?
Why Quality Data is the Foundation of Next-Gen Antibody Development?
Use the arrow buttons to preview report pages
The antibody therapeutics market is exploding.
$865 billion by 2032. Google DeepMind's $3 billion partnerships. AstraZeneca's $5.3 billion AI deal. Everyone's betting AI will revolutionize drug discovery.
But there's a critical problem: Most AI models are being trained on fragmented, unreliable data buried in patents and questionable databases. The result? The same 10-15 year timelines and $2+ billion costs that have plagued the industry for decades.
Leading companies are taking a different approach. They're solving their data foundation first—and seeing dramatic results.
Download this report to discover:
✓ The 8 critical data types your AI models need (most companies are missing 5-7 of them)
✓ How to compress months of wet-lab work into days using comprehensive antibody-antigen datasets
✓ Real case studies of companies cutting development timelines in half through better data strategy
✓ The specific data requirements that actually make AI work in antibody development
✓ Why traditional data collection approaches fail—and what leading R&D teams do instead
The competitive window is closing fast. With 37,500+ active trials and new AI partnerships launching monthly, the companies that solve their data challenges now will capture the biggest share of the $865B opportunity.
.png?width=5501&height=1046&name=Patsnap_Logo-01%20(1).png "Patsnap_Logo-01 (1)"){kind=logo}